Related Experiment Video
Updated: Jun 17, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers
Katrin Kristjansdottir1, Don Dizon
1Warren Alpert Medical School of Brown University, Women and Infants Hospital of Rhode Island - Program in Women's Oncology, 101 Dudley Street, Providence, Rhode Island, USA.
Importance Of The Field:
Pertuzumab is a human EGF receptor (HER)-dimerization inhibitor that represent a novel class of agents aimed at blocking HER2 from pairing with other receptors of the HER family. In this review, we discuss the background and scientific rationale, related to pertuzumab as it has undergone development for women's cancers.
Areas Covered In This Review:
Pre-clinical and clinical trials, published or presented at national meetings from 1995 to the present, are included in this review.
What The Reader Will Gain:
A Phase II trial in HER2-positive metastatic breast cancer showed promising activity of pertuzumab when it was combined with trastuzumab and a randomized Phase III trial is now underway. Pertuzumab, when evaluated in recurrent ovarian cancer showed limited activity when combined with chemotherapy in platinum-sensitive and platinum-resistant disease. However, a recent subset analysis suggests that HER3 mRNA levels may predict response to pertuzumab in ovarian cancer.
Take Home Message:
HER-dimerization inhibitors represent a novel mechanism of inhibition of HER pathways. Pertuzumab may play a role in the management of HER2-positive breast cancer. The potential benefit of pertuzumab in ovarian cancer is unclear, but low HER3 levels may suggest a sub-group of patients that can benefit from pertuzumab.
Insights
Pertuzumab, a novel HER-dimerization inhibitor, shows promise in HER2-positive breast cancer management. Its role in ovarian cancer is unclear, but HER3 levels may identify patients who could benefit.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Pertuzumab is a novel HER-dimerization inhibitor targeting the Epidermal Growth Factor Receptor (EGFR) family.
- It blocks Human Epidermal growth factor Receptor 2 (HER2) dimerization with other HER family members.
- This review covers the scientific rationale behind pertuzumab's development for gynecological cancers.
Purpose of the Study:
- To review the development and scientific basis of pertuzumab.
- To evaluate pertuzumab's efficacy in women's cancers, specifically breast and ovarian cancers.
- To explore potential predictive biomarkers for pertuzumab response.
Main Methods:
- Comprehensive review of pre-clinical studies.
- Analysis of clinical trials published or presented from 1995 to the present.
- Inclusion of data from national scientific meetings.
Main Results:
- Phase II trial demonstrated promising activity of pertuzumab combined with trastuzumab in HER2-positive metastatic breast cancer.
- A randomized Phase III trial for breast cancer is currently ongoing.
- Pertuzumab showed limited activity in recurrent ovarian cancer when combined with chemotherapy, but HER3 mRNA levels may predict response.
Conclusions:
- HER-dimerization inhibitors offer a novel approach to inhibiting HER pathways.
- Pertuzumab holds potential for managing HER2-positive breast cancer.
- The utility of pertuzumab in ovarian cancer requires further investigation, with potential benefit in a subgroup with low HER3 levels.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle